Endoluten
Also known as: pineal peptide · Khavinson pineal bioregulator
A Khavinson pineal peptide preparation covering the pineal-gland-directed bioregulator angle alongside Epitalon — used in Russian gerontology practice for circadian and gerontoprotective effects.
Endoluten is a Khavinson pineal peptide preparation covering the pineal-directed bioregulator angle alongside Epitalon in Russian gerontology practice.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neuroprotection
- Half-life
- Complex preparation with multiple components and varied pharmacokinetics
Section 1
Overview
Endoluten is a pineal peptide preparation from the Khavinson bioregulator programme, positioned as the pineal-directed component in the broader St. Petersburg Institute framework alongside Epitalon (the synthetic short-peptide analogue) and the other tissue-directed bioregulators. Where Epitalon is a defined tetrapeptide (Ala-Glu-Asp-Gly), Endoluten is a peptide preparation with a more complex composition, sitting closer to the Cortexin / Cerebrolysin architectural pattern (multi-component preparation) than to the Pinealon / Epitalon architectural pattern (defined short peptide).
The compound's positioning in Russian bioregulator practice is as a pineal-directed intervention with effects on circadian regulation, melatonin-rhythm restoration, and the broader gerontoprotective endpoints associated with pineal function. It is often used alongside Epitalon in cyclical protocols, providing the multi-component-preparation angle to complement the defined-peptide angle from Epitalon.
The cognitive-relevance is indirect via the circadian and gerontoprotective mechanisms. Direct cognitive-endpoint research is limited; the cohort-level Russian gerontology work reports outcomes on age-related morbidity and mortality rather than on specific cognitive endpoints.
Section 2
Discovery & History
- Developed at the St. Petersburg Institute of Bioregulation and Gerontology under Khavinson's direction as the pineal peptide preparation arm of the broader bioregulator programme.
- Positioned as the multi-component-preparation analogue to Epitalon within the pineal-directed research pathway.
- Used in Russian clinical and research practice as part of cyclical bioregulator protocols; not approved as a medicine in Western jurisdictions.
- Long-term Russian cohort work covers Endoluten alongside other Khavinson bioregulators but rarely as the sole intervention.
- Remains a research chemical in the UK; supply through non-Russian channels is limited and variable.
Section 3
Mechanism of Action
- 1Multi-component peptide preparation targeting the pineal-gland-relevant transcriptional programme — the mechanism-of-action framework parallels Cerebrolysin's architecture (complex preparation with multiple bioactive components) applied to pineal-directed rather than whole-brain-directed effects.
- 2Restoration of melatonin-rhythm amplitude in aged cohorts with age-blunted circadian melatonin secretion — the phenotypic biomarker of the pineal-targeting claim, reproducibly demonstrated in Russian chronobiology research.
- 3Antioxidant effects at the pineal-gland and adjacent tissues, contributing to the gerontoprotective framework via preservation of pineal-cell mitochondrial function and reduced age-related pineal atrophy.
- 4Reported effects on neuroendocrine ageing markers alongside the circadian effects — modulation of gonadotropin, growth-hormone, and cortisol axes in aged research subjects.
- 5Modulation of the HPA-axis stress response via the pineal-adrenal-axis interconnection, providing an indirect stress-resilience angle to the pineal-directed positioning.
- 6Indirect cognitive effects through circadian consolidation of sleep-mediated memory processing — the same mechanism-of-action angle that positions Epitalon on this cognitive-peptide reference.
- 7Reported immunomodulatory effects via the pineal-immune axis, extending the pharmacology into the age-related immune-senescence research context.
- 8Effects on cellular telomere maintenance in some preclinical work, echoing the telomerase-induction mechanism most associated with Epitalon within the same Khavinson framework.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Circadian rhythm restoration in aged cohorts with disrupted melatonin secretion — the flagship phenotypic outcome and the mechanistic root for the broader gerontoprotective claims.
- 2Part of the broader Khavinson gerontoprotective programme with long-term Russian cohort data supporting reduced age-related morbidity and mortality across multi-year follow-up.
- 3Complements Epitalon's defined-tetrapeptide approach with a complex-preparation angle, providing a research-configuration option for research designs seeking both defined-peptide and preparation-based bioregulator effects.
- 4Well-tolerated in the reported Russian clinical experience across paediatric, adult, and elderly populations with adverse-event rates comparable to placebo.
- 5Reported effects on subjective sleep quality, subjective wellbeing, and objective sleep-architecture markers in Russian elderly-population research.
- 6Neuroendocrine-ageing-marker normalisation in some cohort work, particularly on gonadotropin and cortisol axes.
- 7Immunomodulatory effects with relevance to age-related immunosenescence research.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Sublingual / parenteral (research) | Preparation-specific doses following the Khavinson clinical convention — typically 5–20 mg per session depending on the specific preparation form | Cyclical, typically 10-day courses at once-daily dosing | Repeated every 4–6 months rather than continuous administration; multi-year cyclical use in gerontoprotective protocols |
Note: The multi-component preparation is not directly comparable to defined-peptide dosing conventions; specific dose-response characterisation follows the Khavinson clinical practice framework rather than modern-Western dose-titration methodology.
Section 6
Administration Routes
- Sublingual administration — a common route for Khavinson peptide preparations, exploiting direct oral-mucosa absorption to bypass gastric proteolysis.
- Parenteral (subcutaneous, intramuscular) routes in some Russian clinical protocols where systemic exposure and sustained pharmacokinetic profile is prioritised.
- Intranasal administration in some research applications, particularly for cognitive-endpoint research designs.
- Oral administration is not viable for a peptide-based preparation — gastrointestinal proteolysis efficiently degrades the bioactive components.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in the reported Russian clinical experience across the paediatric-to-elderly age spectrum.
- · Occasional mild transient effects during initial dosing — mild sleepiness or dream-quality alteration consistent with the melatonin-modulating mechanism, resolving within the first several doses.
- · The Khavinson-family unusually clean acute-tolerability profile extends to Endoluten across the reported research contexts.
- · Occasional local irritation at parenteral administration sites.
Rare / theoretical
- · Long-term safety data outside the Khavinson group is very sparse; independent Western replication of the multi-year cohort work has not been performed.
- · Multi-component-preparation compositional variability is a theoretical concern — batch-to-batch consistency for a complex biological preparation requires standardised manufacturing which the market may not uniformly deliver.
- · Rare hypersensitivity reactions — theoretical concern based on peptide-preparation chemistry rather than documented clinical experience.
- · Theoretical interaction with pineal-active pharmaceuticals (melatonin agonists, sleep-active hypnotics) given the shared pineal-endpoint mechanism.
Contraindications
- · Not licensed for human use in the UK — supply for human consumption is prohibited under the Human Medicines Regulations 2012.
- · Pregnancy and lactation — no controlled human data.
- · Concurrent use with pineal-active pharmaceuticals (melatonin agonists / antagonists) should be evaluated for potential interaction.
- · Severe pineal-region pathology (pineal tumours, pinealectomy status) — the pineal-directed mechanism is not characterised in these baselines.
Section 8
UK & EU Regulatory Context
United Kingdom
Not a licensed medicine in the UK. Research chemical only.
European Union
Not approved by the EMA. Used in Russian bioregulator practice.
Section 9
Clinical Studies Summary
Endoluten in Khavinson gerontoprotective cohort research
Cohort-level Russian gerontology work including Endoluten as one component of multi-bioregulator protocols across multi-year follow-up in elderly populations, reporting reductions in age-related morbidity (cardiovascular events, dementia incidence) and mortality relative to demographic-matched controls. The compound is one component of the broader gerontoprotective protocol rather than the sole intervention, but the cohort work supports continued research interest.
Endoluten and circadian rhythm restoration
Russian preclinical and clinical work characterising Endoluten's effects on melatonin-rhythm amplitude, circadian consolidation, and sleep-architecture markers in aged cohorts. The chronobiology characterisation provides the phenotypic biomarker link between the proposed pineal-directed mechanism and a measurable circadian output, extending the mechanistic-to-behavioural bridge for the compound.
Endoluten compositional and mechanistic characterisation
Characterisation work describing the multi-component composition of the Endoluten preparation and the biochemical signatures of its pineal-tissue-directed activity, providing the architectural framework for its positioning as the preparation-side counterpart to Epitalon's defined-peptide approach within the same conceptual Khavinson framework.
Endoluten neuroendocrine ageing markers characterisation
Endocrinology characterisation study reporting Endoluten's effects on gonadotropin, growth-hormone, and cortisol axis markers in aged research subjects, providing evidence of neuroendocrine-normalising effects that extend beyond the primary melatonin-rhythm-restoration finding and connect the compound to broader neuroendocrine-ageing research contexts.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Endoluten for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Endoluten from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.